000661 长春高新
已收盘 05-19 15:00:00
资讯
新帖
简况
长春高新:2025年度公司实施完毕前一期回购股份的合计成交金额约4亿元
证券之星 · 05-19 20:48
长春高新:2025年度公司实施完毕前一期回购股份的合计成交金额约4亿元
长春高新:国资控股并非企业长期创新发展的障碍
证券之星 · 05-18 20:51
长春高新:国资控股并非企业长期创新发展的障碍
长春高新:公司各项经营、财务指标均符合上市规则要求,不存在相关风险
证券之星 · 05-18 20:51
长春高新:公司各项经营、财务指标均符合上市规则要求,不存在相关风险
长春高新:前次回购最高成交价112.25元/股
证券之星 · 05-18 20:51
长春高新:前次回购最高成交价112.25元/股
长春高新:构建第二增长曲线加大市场推广
证券之星 · 05-17 14:15
长春高新:构建第二增长曲线加大市场推广
长春高新:公司近年大额研发投入均聚焦主业创新管线布局
证券之星 · 05-17 13:57
长春高新:公司近年大额研发投入均聚焦主业创新管线布局
长春高新最新公告:子公司GenSci161注射液获美国FDA批准开展临床试验
证券之星 · 05-15
长春高新最新公告:子公司GenSci161注射液获美国FDA批准开展临床试验
长春高新(000661)披露2025年度股东会决议公告,5月13日股价下跌1.91%
中金财经 · 05-13
长春高新(000661)披露2025年度股东会决议公告,5月13日股价下跌1.91%
长春高新(000661.SZ)子公司伏欣奇拜单抗注射液在境内获批上市
智通财经 · 05-06
长春高新(000661.SZ)子公司伏欣奇拜单抗注射液在境内获批上市
长春高新:相关产品经过1项III期研究和3项II期研究
证券之星 · 04-24
长春高新:相关产品经过1项III期研究和3项II期研究
长春高新:金赛药业由内部临床开发团队负责国内试验
证券之星 · 04-24
长春高新:金赛药业由内部临床开发团队负责国内试验
长春高新:推动新业务成为公司新的业绩增长点
证券之星 · 04-24
长春高新:推动新业务成为公司新的业绩增长点
长春高新业绩下滑延续,净利润下滑九成,生长激素收入跌破百亿
蓝鲸财经 · 04-24
长春高新业绩下滑延续,净利润下滑九成,生长激素收入跌破百亿
长春高新最新公告:子公司GenSci144片临床试验申请获受理
证券之星 · 04-22
长春高新最新公告:子公司GenSci144片临床试验申请获受理
【私募调研记录】丹羿投资调研仕佳光子、长春高新
证券之星 · 04-22
【私募调研记录】丹羿投资调研仕佳光子、长春高新
【私募调研记录】彤源投资调研长春高新
证券之星 · 04-22
【私募调研记录】彤源投资调研长春高新
长春高新2025年净利润同比下降94%;翰森制药公布抗失眠新药临床数据|医药早参
每日经济新闻 · 04-22
长春高新2025年净利润同比下降94%;翰森制药公布抗失眠新药临床数据|医药早参
长春高新(000661)披露2025年年度报告,4月21日股价上涨1.51%
证券之星 · 04-21
长春高新(000661)披露2025年年度报告,4月21日股价上涨1.51%
长春高新最新公告:第一季度净利润同比下降41.67%
证券之星 · 04-21
长春高新最新公告:第一季度净利润同比下降41.67%
长春高新:构建第二增长曲线加大市场推广
证券之星 · 04-20
长春高新:构建第二增长曲线加大市场推广
加载更多
公司概况
公司名称:
长春高新技术产业(集团)股份有限公司
所属行业:
医药制造业
上市日期:
1996-12-18
主营业务:
长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售。公司的主要产品是注射用人生长激素、重组人生长激素注射液、注射用重组人促卵泡激素、重组人促卵泡激素注射液、醋酸曲普瑞林注射液、伏欣奇拜单抗、屋尘螨变应原制剂、醋酸甲地孕酮口服混悬液、口腔凝胶、水痘减毒活疫苗、带状疱疹减毒活疫苗、冻干鼻喷流感减毒活疫苗、鼻喷流感减毒活疫苗、银花泌炎灵片、清胃止痛微丸、血栓心脉宁片、疏清颗粒。
发行价格:
8.80
{"stockData":{"symbol":"000661","market":"SZ","secType":"STK","nameCN":"长春高新","latestPrice":83.38,"timestamp":1779174198000,"preClose":82.62,"halted":0,"volume":2946304,"delay":0,"changeRate":0.0092,"floatShares":400000000,"shares":408000000,"eps":-0.103,"marketStatus":"已收盘","change":0.76,"latestTime":"05-19 15:00:00","open":82.7,"high":83.66,"low":82.7,"amount":245000000,"amplitude":0.0116,"askPrice":83.39,"askSize":29,"bidPrice":83.38,"bidSize":278,"shortable":0,"etf":0,"ttmEps":-0.103,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779240600000},"marketStatusCode":5,"adr":0,"adjPreClose":82.62,"symbolType":"stock","openAndCloseTimeList":[[1779154200000,1779161400000],[1779166800000,1779174000000]],"highLimit":90.88,"lowLimit":74.36,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":407937529,"isCdr":false,"pbRate":1.51,"roa":"--","roe":"1.25%","epsLYR":0.39,"committee":0.504873,"marketValue":34014000000,"turnoverRate":0.0074,"status":0,"floatMarketCap":33320000000},"requestUrl":"/m/hq/s/000661","defaultTab":"news","newsList":[{"id":"2636859141","title":"长春高新:2025年度公司实施完毕前一期回购股份的合计成交金额约4亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2636859141","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636859141?lang=zh_cn&edition=full","pubTime":"2026-05-19 20:48","pubTimestamp":1779194914,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新05月19日在投资者关系平台上答复投资者关心的问题。反观长春高新,股价长期低迷估值严重低估,投资者信心持续走弱,却迟迟未见实质二级市场回购。近年来公司已多次实施回购,2025年度公司实施完毕前一期回购股份的合计成交金额约4亿元,后续如再有相关事项公司会按照法律法规要求履行审议披露程序,谢谢!","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900041063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","000661","BK0239","BK0046","BK0188","BK0075","BK0057"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636752520","title":"长春高新:国资控股并非企业长期创新发展的障碍","url":"https://stock-news.laohu8.com/highlight/detail?id=2636752520","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636752520?lang=zh_cn&edition=full","pubTime":"2026-05-18 20:51","pubTimestamp":1779108670,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新05月17日在投资者关系平台上答复投资者关心的问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800034682.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0075","BK0057","BK0028","BK0239","BK0046","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636075783","title":"长春高新:公司各项经营、财务指标均符合上市规则要求,不存在相关风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2636075783","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636075783?lang=zh_cn&edition=full","pubTime":"2026-05-18 20:51","pubTimestamp":1779108668,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新05月17日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好,长春高新存在高风险,长春高新在2025年年报发布后,目前不会退市,但存在一定的退市风险,主要源于持续的业绩下滑和历史资金占用问题。研发投入布局长远创新,多项管线已有实质进展。内控治理持续完善,未发现存在违规占用资金的情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800034679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","BK0028","000661","BK0046","BK0057","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636075275","title":"长春高新:前次回购最高成交价112.25元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2636075275","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636075275?lang=zh_cn&edition=full","pubTime":"2026-05-18 20:51","pubTimestamp":1779108666,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新05月17日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好:公司在股价160元时进行回购,而现在股价在80多时为何不进行回购?长春高新回复:您好,您所提到的160元是公司前次回购价格的上限不超过160元/股,实际执行过程中,公司前次回购的最高成交价为112.25元/股,最低成交价为84.00元/股,不存在高价回购、低价不回购及利益输送情形,前次回购合规完成,依法合规、程序透明。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800034677.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0057","BK0188","BK0239","BK0075","BK0028","000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636096033","title":"长春高新:构建第二增长曲线加大市场推广","url":"https://stock-news.laohu8.com/highlight/detail?id=2636096033","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636096033?lang=zh_cn&edition=full","pubTime":"2026-05-17 14:15","pubTimestamp":1778998510,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新05月17日在投资者关系平台上答复投资者关心的问题。投资者提问:公司销售能效行业最低,研发投入巨大但是毫无建树,管理靡费巨大但是整体上全是负作用,一季度在去年大幅降低92%的情况下再次腰斩!公司整体盈利没有金赛一个子公司多,其他子公司以及行政总部全是负资产,那么请问公司管理层能看到这些问题吗?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700002863.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0188","BK0239","BK0046","BK0075","BK0028","000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636096466","title":"长春高新:公司近年大额研发投入均聚焦主业创新管线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2636096466","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636096466?lang=zh_cn&edition=full","pubTime":"2026-05-17 13:57","pubTimestamp":1778997426,"startTime":"0","endTime":"0","summary":"投资者提问:同为生物药企,药明康德两年研发合计23.58亿元,费用率仅2.46%,经营稳健业绩稳定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700002833.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0046","BK0028","BK0239","000661","BK0188","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635808456","title":"长春高新最新公告:子公司GenSci161注射液获美国FDA批准开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2635808456","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635808456?lang=zh_cn&edition=full","pubTime":"2026-05-15 20:10","pubTimestamp":1778847010,"startTime":"0","endTime":"0","summary":"长春高新(000661.SZ)公告称,公司子公司金赛药业收到美国FDA批准文件,同意GenSci161注射液在美国开展临床试验,用于治疗化脓性汗腺炎。该药品为全人源化双特异性抗体,可同时靶向IL-1α和IL-1β,有望改善中重度患者治疗效果。此前,该药在国内已获批用于子宫内膜异位症等适应症的临床试验。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500039515.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0046","BK0239","BK0188","BK0075","000661","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635178817","title":"长春高新(000661)披露2025年度股东会决议公告,5月13日股价下跌1.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635178817","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635178817?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:07","pubTimestamp":1778666877,"startTime":"0","endTime":"0","summary":"长春高新于近日披露《2025年度股东会决议公告》。公告显示,公司于2026年5月12日召开2025年度股东会,会议由董事会召集,董事长姜云涛主持,采用现场与网络投票相结合方式召开。出席会议股东共780人,代表有表决权股份总数的24.4747%。中小股东对各项议案也均投出同意票。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202605/13/20260513237123.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202605/13/20260513237123.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260513/32221181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0075","BK0028","000661","BK0046","BK0057","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633180403","title":"长春高新(000661.SZ)子公司伏欣奇拜单抗注射液在境内获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2633180403","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633180403?lang=zh_cn&edition=full","pubTime":"2026-05-06 19:53","pubTimestamp":1778068401,"startTime":"0","endTime":"0","summary":"智通财经APP讯,长春高新(000661.SZ)发布公告,近日,公司控股子公司——长春金赛药业有限责任公司(以下简称“金赛药业”)收到国家药品监督管理局核准签发的《药品注册证书》,金赛药业伏欣奇拜单抗注射液的境内生产药品注册上市许可申请获得批准。伏欣奇拜单抗是金赛药业研发的一款新型全人源抗IL-1β单克隆抗体药物,属于治疗用生物制品1类新药,可特异性结合人IL-1β,阻断IL-1β诱导的炎性介质产生,用于成人痛风性关节炎急性发作患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438715.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","BK0028","BK0057","BK0046","BK0188","000661","BK0239","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629811033","title":"长春高新:相关产品经过1项III期研究和3项II期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2629811033","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629811033?lang=zh_cn&edition=full","pubTime":"2026-04-24 17:21","pubTimestamp":1777022471,"startTime":"0","endTime":"0","summary":"长春高新回复:您好,相关产品经过1项III期研究和3项II期研究,共有455例痛风性关节炎患者接受了本品给药,其中350例患者接受了200mg给药,充分评价了本品在痛风性关节炎患者中的安全性,临床数据中未有您提到的食欲相关反应,且目前超万例真实患者使用反馈中,也没有相关反馈。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400051837.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","BK0028","000661","BK0046","BK0057","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629281172","title":"长春高新:金赛药业由内部临床开发团队负责国内试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2629281172","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629281172?lang=zh_cn&edition=full","pubTime":"2026-04-24 17:21","pubTimestamp":1777022466,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新04月24日在投资者关系平台上答复投资者关心的问题。公司在心脑血管方面有没有布局?与众多严重依赖CRO开展国内试验的同行不同,金赛药业直接管理研究者参与、研究中心的筛选与启动、受试者招募、数据锁定,以及与监管部门的沟通及申报工作,有效提升临床试验的效率与质量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400051833.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0057","BK0188","000661","BK0075","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629816532","title":"长春高新:推动新业务成为公司新的业绩增长点","url":"https://stock-news.laohu8.com/highlight/detail?id=2629816532","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629816532?lang=zh_cn&edition=full","pubTime":"2026-04-24 16:15","pubTimestamp":1777018517,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)04月24日在投资者关系平台上答复投资者关心的问题。投资者提问:公司什么能够业绩开始恢复增长?长春高新回复:您好,公司始终致力于通过提升内在价值推动高质量发展,近年来公司主动开展战略调整与强化创新投入,重点推进相关具备较高市场潜力的重点产品的研发及销售工作,并努力推动相关新业务成为公司新的业绩增长点,进一步推进公司多元化转型升级。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400048919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0057","BK0075","000661","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629815377","title":"长春高新业绩下滑延续,净利润下滑九成,生长激素收入跌破百亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2629815377","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629815377?lang=zh_cn&edition=full","pubTime":"2026-04-24 15:55","pubTimestamp":1777017337,"startTime":"0","endTime":"0","summary":"长春高新业绩已经经历两年下滑。长春高新2025年年报中表示,报告期内,长效生长激素等产品参与医保谈判并纳入国家医保目录。百克生物方面解释称,报告期内,行业竞争加剧、民众接种意愿不足、新生儿出生率下降等多重因素影响,公司主要产品营业收入大幅下滑。值得注意的是,长春高新的业绩颓势仍在延续。2026年一季报显示,公司一季度实现营业收入25.87亿元,同比减少13.69%;归母净利润2.76亿元,同比下滑41.67%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1777017292721856806","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629010537","title":"长春高新最新公告:子公司GenSci144片临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2629010537","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629010537?lang=zh_cn&edition=full","pubTime":"2026-04-22 18:50","pubTimestamp":1776855049,"startTime":"0","endTime":"0","summary":"长春高新公告称,公司控股子公司长春金赛药业有限责任公司近日收到国家药品监督管理局核准签发的《受理通知书》,其自主研发的GenSci144片境内生产药品注册临床试验申请获得受理。GenSci144片是一款口服小分子SLC6A19抑制剂,注册分类为化药1类,拟用于苯丙酮尿症的治疗。此次申请获受理有利于公司拓宽业务结构、优化产品结构,丰富战略领域产品线布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200045838.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","000661","BK0057","BK0075","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629706484","title":"【私募调研记录】丹羿投资调研仕佳光子、长春高新","url":"https://stock-news.laohu8.com/highlight/detail?id=2629706484","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629706484?lang=zh_cn&edition=full","pubTime":"2026-04-22 08:12","pubTimestamp":1776816777,"startTime":"0","endTime":"0","summary":"根据市场公开信息及4月21日披露的机构调研信息,知名私募丹羿投资近期对2家上市公司进行了调研,相关名单如下:1)仕佳光子 调研纪要:公司高速光芯片与器件开发及产业化项目涵盖无源与有源光芯片及器件、组件等相关产品的研发与产能建设,目前处于内部审批及前期筹备阶段,需经股东会审议后实施。后续进展均以公司在上交所披露的信息为准。GenSci098项目首付款7000万美元已到账但未确认收入。H股上市申请失效,后续将审慎推进。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026042200015062.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0214","BK0028","BK0057","BK0046","BK0188","000661","BK0239","BK0075","688313"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629061043","title":"【私募调研记录】彤源投资调研长春高新","url":"https://stock-news.laohu8.com/highlight/detail?id=2629061043","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629061043?lang=zh_cn&edition=full","pubTime":"2026-04-22 08:12","pubTimestamp":1776816771,"startTime":"0","endTime":"0","summary":"根据市场公开信息及4月21日披露的机构调研信息,知名私募彤源投资近期对1家上市公司进行了调研,相关名单如下:1)长春高新 调研纪要:2025年度,公司实现营业收入120.83亿元,归母净利润1.55亿元。研发投入达29.36亿元,占营收24.30%,临床阶段管线超40条。GenSci098项目首付款7000万美元已到账但未确认收入。H股上市申请失效,后续将审慎推进。2026年一季度费用下降,公司将聚焦高质量增长,优化资产结构。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026042200015050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0057","BK0075","BK0046","BK0239","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629069622","title":"长春高新2025年净利润同比下降94%;翰森制药公布抗失眠新药临床数据|医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2629069622","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629069622?lang=zh_cn&edition=full","pubTime":"2026-04-22 07:02","pubTimestamp":1776812539,"startTime":"0","endTime":"0","summary":"|2026年4月22日星期三|NO.1长春高新2025年净利润1.55亿元,同比下降94%4月21日,长春高新披露2025年年度报告。2025年,公司实现营业收入120.83亿元,较上年同期降低10.27%;归属于上市公司股东的净利润为1.55亿元,较上年同期降低94%。公司拟向全体股东每10股派发现金红利1.60元(含税),送红股0股,不以公积金转增股本。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604223713055256.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604223713055256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["000661","03692","159938","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629030309","title":"长春高新(000661)披露2025年年度报告,4月21日股价上涨1.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629030309","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629030309?lang=zh_cn&edition=full","pubTime":"2026-04-21 22:12","pubTimestamp":1776780743,"startTime":"0","endTime":"0","summary":"截至2026年4月21日收盘,长春高新报收于88.3元,较前一交易日上涨1.51%,最新总市值为360.21亿元。该股当日开盘86.88元,最高88.5元,最低86.37元,成交额达5.16亿元,换手率为1.48%。近日,长春高新披露《2025年年度报告》。公告显示,公司2025年实现营业收入120.83亿元,同比下降10.27%;归属于上市公司股东的净利润1.55亿元,同比下降94.00%。经营活动产生的现金流量净额为8.02亿元,同比下降74.16%。公司总资产为300.81亿元,归属于上市公司股东的净资产为220.09亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100052875.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0057","BK0046","BK0239","BK0075","BK0188","000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629847210","title":"长春高新最新公告:第一季度净利润同比下降41.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629847210","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629847210?lang=zh_cn&edition=full","pubTime":"2026-04-21 17:34","pubTimestamp":1776764045,"startTime":"0","endTime":"0","summary":"长春高新(000661.SZ)公告称,2026年第一季度实现营业收入25.87亿元,同比下降13.69%;归属于上市公司股东的净利润为2.76亿元,同比下降41.67%。业绩变动主要系本报告期长效生长激素产品销量增长,且该产品单位成本相对较高,导致营业成本增加所致。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100039834.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628723499","title":"长春高新:构建第二增长曲线加大市场推广","url":"https://stock-news.laohu8.com/highlight/detail?id=2628723499","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628723499?lang=zh_cn&edition=full","pubTime":"2026-04-20 20:51","pubTimestamp":1776689466,"startTime":"0","endTime":"0","summary":"公司管理层始终将维护全体股东尤其是中小投资者合法权益作为履职的核心出发点,近年来公司为构建第二增长曲线,对已上市重点新品加大市场推广,叠加研发费用稳步加码、部分产品价格调整,导致利润阶段性摊薄,并非经营不善或费用管控失效,相关投入符合医药创新行业高投入、长周期的客观规律,具备合理性与必要性;同时公司近年来坚守分红承诺,持续落实股东回报规划,相关利润分配及股份回购资金支出增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000034399.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0075","BK0057","BK0188","BK0028","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779236904337,"stockEarnings":[{"period":"1week","weight":-0.0616},{"period":"1month","weight":-0.0374},{"period":"3month","weight":-0.0458},{"period":"6month","weight":-0.1801},{"period":"1year","weight":-0.1789},{"period":"ytd","weight":-0.0991}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":0.0292},{"period":"3month","weight":0.0214},{"period":"6month","weight":0.0607},{"period":"1year","weight":0.2381},{"period":"ytd","weight":0.0506}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"长春高新技术产业(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"138133人(较上一季度增加7.70%)","perCapita":"2892股","listingDate":"1996-12-18","address":"吉林省长春市朝阳区高新区海容酒店及海茵广场写字楼B座2708室","registeredCapital":"40793万元","survey":" 长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售。公司的主要产品是注射用人生长激素、重组人生长激素注射液、注射用重组人促卵泡激素、重组人促卵泡激素注射液、醋酸曲普瑞林注射液、伏欣奇拜单抗、屋尘螨变应原制剂、醋酸甲地孕酮口服混悬液、口腔凝胶、水痘减毒活疫苗、带状疱疹减毒活疫苗、冻干鼻喷流感减毒活疫苗、鼻喷流感减毒活疫苗、银花泌炎灵片、清胃止痛微丸、血栓心脉宁片、疏清颗粒。","listedPrice":8.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"长春高新,000661,长春高新股票,长春高新股票老虎,长春高新股票老虎国际,长春高新行情,长春高新股票行情,长春高新股价,长春高新股市,长春高新股票价格,长春高新股票交易,长春高新股票购买,长春高新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}